deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00390845

P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

A Double-blind Placebo-controlled Study of the Efficacy and Safety of the P38 Map Kinase Inhibitor SB681323 in Patients With Neuropathic Pain Following Nerve Trauma

Sponsor: GlaxoSmithKline

Conditions Pain, Neuropathic
Interventions Placebo SB681323
Updated 9 times since 2017 Last updated: Aug 21, 2017 Started: Aug 30, 2006 Primary completion: Aug 11, 2008 Completion: Aug 11, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00390845, this PHASE2 trial focuses on Pain, Neuropathic and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotCompleted~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Aug 2017 — Sep 2017 [monthly]

    Completed PHASE2

  4. Jan 2017 — Aug 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bochum, Germany , Broadmeadow, Australia , Cambridge, United Kingdom , Cologne, Germany , Glasgow, United Kingdom , Hanover, Germany , Liverpool, United Kingdom , London, United Kingdom , Moscow, Russia , Randwick, Australia and 2 more locations